ABSTRACT
Objective:To explore the effects of different courses of Bifidobacterium combined with bismuth on the eradication rate, ulcer healing rate and adverse reactions in the initial eradication treatment of Helicobacter pylori positive gastric ulcer patients.Methods:From September 2018 to September 2021, 219 patients with gastric ulcer were selected from the outpatient department of gastroenterology department of Kailuan General Hospital Affiliated,all of whom were positive for 13C or 14C-urea breath test and were not treated with Helicobacter pylori eradication. Group A, B and C were randomly divided by Excel, Group A was the control group (73 patients): 14-day bismuth quadruple therapy (Eprazole + colloidal bismuth pectin + amoxicillin + furazolidone); group B (73 patients): 7 days Bifidobacterium tetravaccine tablets (live) was given in the second week of treatment in group A; group C (73 patients): Bifidobacterium tetravaccine tablets (live) was given 14 days on the basis of treatment in group A. 13C or 14C-urea breath test and gastroscope were reexamined after all treatments, to compare the eradication rate, ulcer healing rate and the incidence of adverse reactions.Results:The eradication rates in three groups were 90.8%(59/65), 91.2% (62/68)and 91.0%(61/67) respectively, there was no significant difference among the three groups (χ 2=0.01, P=0.997). The ulcer healing rate in three groups were 93.8%(61/65), 94.1%(64/68) and 95.5%(64/67) respectively, group B and group C were compared with group A, and the difference was not statistically significant(group B: group A P=1.000, group C: group A P=0.716).The incidence of adverse reactions in three groups was 21.4%(15/70), 7.1%(5/70) and 7.0%(5/71) respectively, the difference was statistically significant (χ 2=9.21, P=0.010). The incidence of adverse reactions in group B and C was significantly lower than that in group A (group B: group A χ 2=5.83, P=0.016; group C: groups A χ 2=5.99, P=0.014). Compare means of measurement data among the three groups use analysis of variance. Chi square test, Fisher exact probability method and split chi square test were used to compare the three groups of counting data. Conclusion:14-day Bifidobacterium tetravaccine tablets (live) and the second half of the treatment lasted for 7-day Bifidobacterium Bifidobacterium tetravaccine tablets (live), they are combined separately with bismuth quadruple therapy in the first eradication of Helicobacter pylori positive gastric ulcer patients can significantly reduce adverse reactions, but Bifidobacterium tetravaccine tablets (live) could not significantly improve the eradication rate, and had no promoting effect on the healing of gastric ulcer.
ABSTRACT
Objective:To evaluate the impact of amoxicillin and clarithromycin resistance on the eradication rate of Helicobacter pylori ( H. pylori), and to explore the optimal minimal inhibitory concentration (MIC) breakpoint of amoxicillin and clarithromycin. Methods:From March 2008 to December 2010, patients with H. pylori positive received standard triple therapy to eradicate H. pylori were retrospectively analyzed, 140 patients with H. pylori infetion were included, of which 12 patients did not receive eradication treatment. At 8 to 12 weeks after treatment, the eradication rate of H. pylori of 140 and 128 patients was calculated by intention-to-treat (ITT) and per-protocol population (PP) analysis, respectively. The correlation between amoxicillin and clarithromycin resistance and failure of H. pylori eradication was analyzed. And the relation between different MIC breakpoints of amoxicillin and clarithromycin and failure of H. pylori eradication was also analyzed. Binary logistic regression analysis and consistency test were used for statistical analysis. Results:The results of ITT and PP analysis indicated that the eradication rate of H. pylori of the standard triple therapy was 66.4%(93/140)and 72.7% (93/128), respectively, 95% confidence interval ( CI) 59.3% to 74.3%, and 65.6% to 79.7%, respectively. The results of binary logistic regression analysis showed that amoxicillin resistance (odds ratio ( OR)=6.326, 95% CI 1.090 to 36.725, P=0.040) and clarithromycin resistance ( OR=10.686, 95% CI 4.031 to 28.326, P<0.01) were both independent risk factors of H. pylori eradication failure. The results of consistency test demonstrated that when the MIC breakpoint of amoxicillin was 0.125 mg/L, the correlation between amoxicillin resistance and H. pylori eradication failure was the highest (fair consistency, P<0.05); when the MIC breakpoint of clarithromycin was 2.000 mg/L, the correlation between clarithromycin resistance and H. pylori eradication failure was the highest (moderate consistency, P<0.05). Conclusions:The eradication rate of H. pylori of standard triple therapy dropped to <80%. The decrease of H. pylori eradication rate was related to the resistance of amoxicillin and clarithromycin. The best MIC breakpoints of amoxicillin and clarithromycin were 0.125 and 2.000 mg/L, respectively.
ABSTRACT
As the awareness of the harmfulness of Helicobacter pylori (Hp) infection increases, the indications for Hp eradication continue to expand. "Kyoto Global Consensus Report on Helicobacter pylori Gastritis" puts forward "Hp infected individuals should be offered eradication therapy, unless there are competing considerations" and the statement has been accepted by more and more scholars. In our country, "the confirmed Hp infection" has been listed as an indication for eradication. However, as the antibiotic resistance rate of Hp increases, the eradication rate of Hp is gradually decreasing, and the proportion of people who has failed multiple treatments is increasing. This article was specially written for helping the clinicians to improve the eradication rate of Hp infection.
ABSTRACT
Multiple basic and clinical researches have confirmed the pathogenicity of Helicobacter pylori (Hp). There is no doubt that Hp is a pathogenic bacterium colonizing on stomach. The Chinese consensus on the management of Hp infection has been published and interpreted, which improves the awareness of Hp-related diseases and standardizes the diagnosis and treatment of Hp infection in clinicians. However, the general population in China have relatively insufficient awareness of Hp's harmfulness and knowledge on its prevention strategy. Moreover, the frequency of resistant antibiotics being used in eradication regimens and the proportion of retreatment are still high. This article was specially written for helping the readers to aware of the harmfulness of Hp infection and improving its prevention and control strategies.
ABSTRACT
OBJECTIVE: To investigate the efficacy, safety and compliance of optimized concomitant therapy for the first-line eradication of Helicobacter pylori infection through a prospective, single-center and open-label cohort study. METHODS: From January 2014 to October 2018, 200 nafive patients with Helicobacter pylori infection and dyspepsia received 14 d concomitant therapy (esomeprazole 40 mg, amoxicillin 1 000 mg, clarithromycin 500 mg and tinidazole 500 mg, twice daily orally). Safety and compliance were assessed 1-3 days after eradication. The therapeutic outcome was determined by 13C-urea breath test 4-8 weeks after eradication. Some patients underwent strain culture, antibiotic sensitivity testing and CYP2C19 polymorphism assay. RESULTS: The eradication rates of optimized concomitant therapy: intention-to-treat analysis 88.0% (95% confidence interval 83.0%-92.0%), modified intention-to-treat analysis 91.2% (87.0%-94.8%) and per-protocol analysis 93.0% (89.2%-96.2%). 43.1% of patients had adverse reactions, the majority were mild to moderate, and only 3.0% of patients discontinued medication because of intolerance to adverse reactions. Patients with good compliance accounted for 94.4%. Variate analyses showed that poor compliance and clarithromycin resistance were the independent risk factors for eradication failure. CONCLUSION: Optimized concomitant therapy (14 d duration and double dose of esomeprazole) achieved good efficacy, safety and compliance for the first-line eradication of Helicobacter pylori infection.
ABSTRACT
In the eradication of Helicobacter pylori, China has carried out more than 30 years of efforts. The treatment plan has evolved, but the eradication rate has not increased significantly, and even has a downward trend. How to improve the eradication rate of Helicobacter pylori is an urgent problem for our clinicians. Combined domestic and foreign literature with new clinical progress, this paper reviews from many aspects, such as Hp related factors, drug factors, patient factors, other factors, and many other aspects, in order to provide some help for clinical treatment.
ABSTRACT
OBJECTIVE: To compare the eradication rate, adverse reactions and compliance of the two 14-day bismuth-containing quadruple therapies in Liaoning Province as the first-line Helicobacter pylori(HP) eradication programs. METHODS: We collected222 eligible HP-infected patients who were admitted to the First Affiliated Hospital of China Medical University from March 2017 to October 2018 and treated with either of the following two programs:(1) EBLA group: esomeprazole(20 mg, twice a day), bismuth(200 mg, twice a day), levofloxacin(200 mg, twice a day) and amoxicillin(1 g, twice a day), 111 cases in total;(2) EBCA group:esomeprazole(20 mg, twice a day), bismuth(200 mg, twice a day), clarithromycin(500 mg, twice a day) and amoxicillin(1 g, twice a day), 111 cases in total. The patients in both groups were given medicines for 14 days, and the 13 C breath test was performed after4 weeks of withdrawal. RESULTS: The eradication rate of EBLA group was 87.34%(95%CI 80.9%-93.9%), and that of EBCA group was 83.33%(95%CI 76%-90.7%).There was no significant difference between the two groups(P=0.413). The incidence of adverse reactions was 10.8% in EBLA group and 26.13% in EBCA group. The difference was statistically significant(P=0.003). The compliance of patients in EBLA group was 99.10%, and that of EBCA group was 98.20%. The difference was not statistically significant(P=0.561).CONCLUSION: Both EBLA program and EBCA program can achieve good eradication rate and compliance in Liaoning province. The incidence of adverse reactions in EBLA group is lower than that in EBCA group, which is the preferred first-line HP eradication program.
ABSTRACT
Objective To evaluate the efficacy and safety of common therapy and individualized treatment in newly diagnosed patients with Helicobacter pylori (H.pylori) infection.Methods From March 2008 to February 2010,September 2013 to April 2014,January to October 2015,a total of 1 440 patients with H.pylori infection who received eradication therapy and with complete clinical data were retrospectively enrolled.Each was 350 cases in individualized treatment group,clarithromycin and bismuth containing quadruple therapy group and concomitant therapy group.A total of 100 cases were in standard triple therapy group,90 cases in sequential therapy group,and 200 cases in levofloxacin and bismuth-containing quadruple therapy group.The eradication rate of H.pylori,incidence of adverse events and compliance rate were compared in the six groups.Chi square test was performed for statistical analysis.Results The results of intention-to-treat analysis indicated that there was no statistically significant difference in H.pylori eradication rates among six groups (x2 =0.985,P=0.323).However,the results of modified intention-to-treat analysis showed that H.pylori eradication rate of individualized treatment group was the highest (92.5％ (282/305) and 93.3％ (278/298)),second was levofloxacin and bismuth-containing quadruple therapy group (90.3％ (167/185) and 91.6％ (164/179)),and the differences were statistically significant (x2 =11.285 and 13.981,both P＜0.01).There was statistically significant difference in indcidence of adverse events among the six groups (x2 =5.692,P=0.018),the incidence of adverse events in levofloxacin and bimuth-containing quadruple therapy group was lowest (16.2 ％ (30/185)),and second was individualized treatment group (21.0％ (64/305)).There was statistically significant difference in compliance rates among the six groups (x2 =4.712,P=0.023),the compliance rates of standard triple therapy group and sequential therapy group were highest (100％ (100/100) and 100％ (90/90)),and second was individualized treatment group (97.7％ (298/305)).Conclusions Both the levofloxacin and bimuth-containing quadruple therapy group and individualized treatment group can effectively eradicate H.pylori infection.The former may be safe and effective to patients unable to receive individualized therapy.
ABSTRACT
Background: Helicobacter pylori (Hp) infection is associated with a variety of gastrointestinal diseases.Studies have shown that Hp eradication rate may be affected by the disease type and stage of disease progression.Aims: To investigate the influence of endoscopic ulcer stage on Hp eradication rate.Methods: A total of 423 peptic ulcer (PU) patients with Hp infection from January 2015 to July 2016 at the People's Hospital of Xinjiang Uygur Autonomous Region were enrolled.Of them,133 were gastric ulcer (GU) and 255 were duodenal ulcer (DU).A 14-day bismuth quadruple therapy was given for Hp eradication,and the eradication rates were analyzed with the endoscopic ulcer stage.Univariate analysis was conducted to identify factors influencing the eradication rate.Results: There was no significant difference in Hp eradication rates between GU and DU groups (82.7％ vs.83.9％,P>0.05).The eradication rates according to endoscopic ulcer stage were significantly different in GU group (active stage vs.inactive stage: 89.0％ vs.75.0％,P＜0.05);but in DU group,the eradication rate in active stage was similar to that in inactive stage (85.6％ vs.83.0％,P>0.05).Univariate analysis revealed that ulcer stage was correlated with the success rate of eradication;the eradication rate in active stage was significantly higher than that in inactive stage (87.8％ vs.80.3％,P＜0.05).Conclusions: Endoscopic ulcer stage is correlated with the Hp eradication rate in PU,especially GU patients.Hp eradication therapy performed in patients with active PU could yield a higher eradication rate.
ABSTRACT
Objective:To evaluate effect of telephone follow-up combined with written instruction on compliance and Helicobacterpylori (H.pylori) eradication in patients with H.pylori infection.Methods:A total of 160 H.pylori positive patients were randomly divided into an experimental group and a control group (n=80 in each group).Ml the patients got the guide instruction named the guidance of clinical medication for H.pylori infection patients before the treatment.The patients in the experimental group were added individualized follow-up with telephone.The compliance,eradication ofH.pylori,adverse events,and satisfaction were compared between the 2 groups.Results:The eradication rate of H.pylori in the perprotocol analysis for the experimental group and control group were 64.4％ (47/73) and 56.5％(35/62),respectively (P=0.380),while in the intention-to-treat analysis,the rates were 58.8％ (47/80) and 43.8％ (35/80,P=0.082),respectively.The compliance rate in the experimental group was significantly higher than that in the control group (91.3％ vs 77.5％,P＜0.05).There was significant difference in patients' satisfaction in good ones (75.3％ vs 51.6％) and poor ones (5.5％ vs 21.0％) between the 2 groups (P＜0.05).There were 11 patients in the experimental group and 36 patients in the control group,who appeared adverse reactions such as nausea,bad breath,abdominal distention,poor appetite,and defecation habit change during the process of eradicating H.pylori,but the occurrence rate in the experimental group was obviously lower than that in the control group (15.1％ vs 58.1％,P＜0.05).Conclusion:The telephone follow-up cannot increase the H.pylori eradication rate,but it can improve compliance and satisfaction for the patients and relieve adverse effects.
ABSTRACT
Objective To compare the efficacy of bismuth-containing quadruple therapy on H.pylori eradication for 10 days versus 14 days in a randomized controlled trial.Methods A total of 240 patients diagnosed with H.pylori infection were randomly assigned to two groups:treated with esomeprazole,bismuth,clarithromycin and amoxicillin for 10 days(n =117) and for 14 days (n =123).Eradication was defined by rapid urease test or 13C-urea breath test at 4 weeks after drug withdrawal.Results A total of 219 patients were complete the trial.Intention-to-treat(ITT) analysis showed that the eradication rate of 10 and 14 days were 77.8％ (91/117)and 76.4％ (94/123)respectively.Per protocol(PP) analysis indicated that the eradication rate of 10 and 14 days were 85.8％ (91/106) and 83.2％ (94/113) respectively.There was no statistically significant differences between the two groups(P ＞ 0.05).The incidence of adverse events were 7.7％ (9/117)and 9.8％ (12/123),respectively.There was no significant difference (P ＞ 0.05).Conclusion The eradication rate of bismuth-containing quadruple therapy for 10 days and 14 days were essentially identical,bismuth-containing quadruple therapy for 10 days has a higher potency ratio.
ABSTRACT
AIM To evaluate the bactericidal activity of Qingre Huashi Formula (Coptidis Rhizoma,Gardeniae Fructus,Taraxaci Herba,etc.) against Helicobacter pylori in infected mice and the effects on NF-κB p65,IL-1 β,IL-8 and TNF-α expression levels.METHODS Forty-four SPF KM mice were randomly divided into four groups,blank control,model control,Qingre Huashi Formula and triple therapy (metronidazole,clarithromycin and lansoprazole) groups.Except the blank control group,mice in another three groups were infected with H.pylori through short-term immunosuppression combined with oral infection.Administration lasted for four weeks.All mice were sacrificed.Rapid urease test (RUT) and histological staining were performed to identify the eradication of H.pylori.HE staining was applied to observing the H.pylori colonization degree and gastric mucosal inflammation.NF-κB p65,IL-1 β,IL-8 and TNF-α expression levels in gastric mucosa were measured through fluorescentquantitative PCR and immunohistochemistry.RESULTS H.pylori eradication rates were model control 0/10,Qingre Huashi Formula 3/10,triple therapy 7/10.Under the light microscope observation,model control group possessed massive H.pylori colonization and partial inflammatory cell infiltration.In triple therapy group,H.pylori colonization and inflammation was slight.Qingre Huashi Formula group had much local accumulation of H.pylori with no obvious inflammatory cell infiltration.The Il1b,Il8,Tnfa and Nfkb p65 mRNA expression levels of triple therapy and Qingre Huashi Formula groups were significantly higher than those of model control group.Immunohistochemistry results displayed no statistical significance among triple therapy,model control and Qingre Huashi Formula groups in the ratio of nucleus/cytoplasm optical density.CONCLUSION Qingre Huashi Formula has a limited eradication activity against H.pylori in infected mice with an obvious improvement of gastric mucosa inflammation.The Ill b,Il8,Tnfa and Nfkb p65 mRNA expression levels of Qingre Huashi Formula and triple therapy groups' markedly increasing with similar expression tendency is possibly related to the negative feedback effect induced by inhibition of protein levels,thus affects the occurance of inflammatory.
ABSTRACT
The indication for eradication of Helicobacter pylori( Hp)has been gradually expanded from peptic ulcer to“confirmed Hp infection”. Kyoto global consensus report on Hp gastritis has defined Hp gastritis as an infectious disease, and proposed that eradication therapy should be given to Hp infected individuals unless there are competing considerations. Currently the issue of Hp infection is no longer whether it should be eradicated,but rather how it can be effectively eradicated. With the rise of antibiotic resistance,Hp eradication is much more difficult than beforehand. This series of lectures on how to improve the eradication rate of Hp has been elaborated in detail in following aspects:current status of Hp eradication therapy,how to improve the eradication rate of drug-resistant strains of Hp,and to explore suitable eradication regimens for Chinese patients in reference with international consensus.
ABSTRACT
Objective To evaluate the effecacy of Bifidobacterium viable triple capsule on anti-Helicobacter pylori (Hp) treatment and its adverse reactions during eradication therapy .Methods T rials on the effect of Bifidobacterium viable triple capsule on Hp eradication were analyzed by Meta-analysis with the software Stata 12 .0 for comprehensive quantitative analysis of its clinical efficacy and adverse reactions during treatment .Results Eight randomly controlled trials (n=114 4) were includ-ed .Pooled Hp eradication rates were 85.91% and 69 .21% for patients with and without Bifidobacterium viable triple capsule respectively ,with the odds ratio (OR) being 3 .07 (95% CI=2 .25~4 .19 ,test for overall effect Z= 7 .08 , P<0 .01);the occurrences of total adverse reactions were 7 .58% and 20.87% respectively ,with the summary OR being 0 .42 (95% CI=0 .29~0 .61 ,test for overall effect Z= 4 .48 , P< 0 .01) .The difference of the two groups was statistically significant . Conclusion Current evidence shows that Bifidobacterium viable triple capsule could increase eradication rate of anti-Hp treat-ment and improve adverse reactions during therapy .
ABSTRACT
Helicobacter pylori is closely related to many digestive system diseases,such as chronic gas-tritis,digestive ulcer,gastric mucosa associated lymphoid tissue lymphoma and gastric cancer,also leads to chil-dren with iron deficiency anemia,growth retardation,asthma,allergic diseases etc. So it is a key strategy to pre-vent and treat these diseases by eradicating Helicobacter pylori. Due to the increasing rates of antimicrobial resist-ance of clarithromycin and metronidazole,the eradication rate of standard triple therapy is 1ess than 80%in re-cent years. Especially in areas of high clarithromycin resistance and standard triple therapy have not been recom-mended as first-line therapy,it is necessary to investigate a new therapeutic strategy to improve the eradication rate of Helicobacter pylori. The new treatments for eradication of Helicobacter pylori in children is mainly based on sequential therapy,bismuth-based therapy,concomitant therapy and probiotics treatment. This article reviews the research progress of the new treatments in recent years.
ABSTRACT
Objective To systematically investigate the pretreatment impact of proton pump inhibitor (PPI) on Helicobacter pylori (HP) eradication rate .Methods PubMed ,EMBASE ,Cochrane database ,Web of Science ,Clinical trial .gov ,SinoMed ,China National Knowledge Internet ,WANFANG Data ,VIP database and Google Scholar were used to search for randomized controlled trials(RCT) .HP eradication rate was calculated by per‐protocol analysis (PP) .RevMan 5 .2 was applied to analyze data .Results There were 10 articles included (982 cases) ,43 cases didn′t meet the program have been removed ,a total of 939 cases included .The result showed that there was no significant difference between the pretreatment of PPI group and the control group ,RR= 0 .99 (95% CI:0 .95-1 .04 ,P=0 .75) .Conducted a subgroup analysis according to eradication regimen ,regimen combining a PPI ,amoxi‐cillin and clarithromycin and regimen combining a PPI ,clarithromycin and metronidazole the pooled risk ratio were 1 .02(95% CI:0 .90-1 .14 ,P=0 .79)and 1 .02(95% CI:0 .92-1 .12 ,P=0 .74)respectively ,there were no significant difference as well .Conclusion The pretreatment with PPI does not affect HP eradication rates of triple or quadruple therapies for HP eradication .We can eradi‐cate HP directly for the patients who have used PPI but were diagnosed to be positive to HP .
ABSTRACT
BACKGROUND/AIMS: Eradication of Helicobacter pylori is a main treatment of peptic ulcer disease. A triple therapy comprised of a proton pump inhibitor, clarithromycin, and amoxicillin is the most commonly used treatment for H. pylori eradication. The eradication of H. pylori infection requires combination of antibiotics. However, development of antibiotic resistance is a major cause of treatment failure. MATERIALS AND METHODS: This study was to observe H. pyrori eradication rate change for 10 years. From August 2005 to June 2014, a total of 4,891 patients with H. pylori infection were treated with standard H. pylori triple eradication therapy (proton pump inhibitor, amoxicillin, clarithromycin) and were analyzed by urea breath test. RESULTS: The overall rates of eradication with standard triple therapy was 82.8% (4,048/4,891). H. pylori eradication rates decreased from 92.2% in 2005 to 80.2% in 2014 (P=0.037). CONCLUSIONS: This study shows that the overall rate of H. pylori eradication with standard triple therapy decreased meaningfully for 10 years.
Subject(s)
Humans , Amoxicillin , Anti-Bacterial Agents , Breath Tests , Clarithromycin , Drug Resistance, Microbial , Helicobacter pylori , Peptic Ulcer , Proton Pumps , Retrospective Studies , Treatment Failure , UreaABSTRACT
Objective To evaluate the efficacy of modified quadruple therapy for patients who were failed in previous Helicobacter pylori ( Hp) eradication treatment .Methods A total of 86 patients with confirmed Hp infection and failed in previous Hp eradication treatment were collected from Qingdao Municipal Hospital during January 2012 and January 2014.Patients were randomly assigned into two group:43 patients in control group were given conventional quadruple therapy ( rabeprazole +colloidal bismuth pectin +amoxicillin +clarithromycin for 14 d ) , and 43 patients in test group were given modified quadruple therapy ( rabeprazole +colloidal bismuth pectin +amoxicillin +clarithromycin for 7 d, and lansoprazole +colloidal bismuth pectin +levofloxacin +metronidazole for 7 d).Chi square test was performed to analyze per-protocol (PP) eradication rates, intent-to-treat (ITT) eradication rates, and Hp recurrence rates between two groups .Results Among 43 patients in test group , 42 completed treatments with PP eradication rate of 100.00% and ITT eradication rate of 97.67%.All patients in control group completed treatments , and Hp eradication was observed in 24 patients , and both PP and ITT eradication rates were 55.81%.The differences in PP and ITT eradication rates between two groups were of statistical significance (χ2 =23.90 and 21.11, P0.05).Conclusion The efficacy of modified quadruple therapy for patients who were failed in the previous Hp eradication treatment is satisfactory.
ABSTRACT
Background:In the treatment of many gastric diseases,eradication of Helicobacter pylori( Hp)is important. With the increasing in antibiotic resistance of Hp,the eradication efficacy of conventional triple and quadruple therapy for Hp is decreasing in recent years. Aims:To assess the efficacy and safety of quadruple therapy combined with astragalus membranaceus for Hp eradication. Methods:A total of 395 Hp-infected patients with chronic gastritis/dyspepsia and peptic ulcer diagnosed by gastroscopy were enrolled,of them 185 patients were of chronic gastritis/dyspepsia group and 210 patients were of peptic ulcer group. Patients in the two groups were subdivided into trial group and control group. Patients in trial group were given quadruple therapy combined with astragalus membranaceus for 14 days,and patients in control group were given quadruple therapy only for 14 days. Hp eradication was assessed by 13 C-urea breath test 4 weeks after treatment. Results:A total of 358 patients(90. 6%)completed the study. In chronic gastritis/dyspepsia group,the eradication rate was significantly higher in trial group than in control group by PP analysis(P0. 05). In peptic ulcer group,the eradication rates by PP and ITT analysis showed no significant differences between trial group and control group(P>0. 05). In control group,the eradication rates by PP and ITT analysis were significantly higher in peptic ulcer group than in chronic gastritis/dyspepsia group( P 0. 05 ). The incidence of adverse effects was not significantly different between chronic gastritis/dyspepsia group and peptic ulcer group as well as trial group and control group( P>0. 05). Conclusions:Quadruple therapy combined with astragalus membranaceus could increase the eradication rate of Hp in chronic gastritis/dyspepsia group safely.
ABSTRACT
Objective To observe the effect of lactoferrin supplementation combined with standard triple therapy on eradication rate of Helicobacter pylori (H.pylori) and its adverse reaction in children. Methods A total of 90 children who were diagnosed with H.pylori infection from January 2012 to January 2013 and had never received eradicative treatment were ran-domly divided into two groups. Forty-five children in control group received the standard triple therapy and another 45 children in observation group received lactoferrin supplementation combined with standard triple therapy. Adverse reaction during the treatment was recorded and eradication rate of H.pylori at 4 weeks after treatment was observed. Results The eradication rate of H.pylori in observation group (91.11%, 41/45) was higher than that in control group (73.33%, 33/45) and the adverse reaction rate in observation group (4.44%, 2/45) was lower than that in control group (20.00%, 9/45).The differences were significant (P<0.05). Conclusions Lactoferrin supplementation combined with standard triple therapy can increase H.pylori eradication rate and reduce the occurrence of adverse reaction.